Concomitant increases in spectrum and level of drug resistance in Mycobacterium tuberculosis isolates

International Journal of Tuberculosis and Lung Disease

Volumn 14, Issue 11, 2010, Pages 1436-1441

  Sun, Z ^a   Zhang, J ^a   Song, H ^b   Zhang, X ^a   Li, Y ^a   Tian, M ^a   Liu, Y ^a   Zhao, Y ^a   Li, C ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b QINGDAO INSTITUTE OF BIOENERGY AND BIOPROCESS TECHNOLOGY   (China)

Author keywords

Drug resistance; M. Tuberculosis; Resistance spectrum

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; OFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

AGAR DILUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; ISONIAZID; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; RIFAMPIN; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 78049432931     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Dooley S W, Jarvis W R, Martone W J, Snider D E. Multi-drug resistant tuberculosis. Ann Intern Med 1992; 117: 257-259.
2. World Health Organization. Case definition for extensively drug-resistant tuberculosis. Wkly Epidemiol Rec 2006; 81: 408.
3. Holtz T H. XDR-TB in South Africa: revised definition. PLoS Med 2007; 4: e161.
4. World Health Organization. WHO Global Task Force outlines measures to combat XDR-TB worldwide. Geneva, Switzerland: WHO, 2006. http://www.who.int/ mediacentre/news/notes/2006/np29/en/index.html Accessed August 2010.
5. World Health Organization/International Union Against Tuberculosis and Lung Disease Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Anti-tuberculosis drug resistance in the world. WHO/HTM/TB/2008.394. 4th global report. Geneva, Switzerland: WHO, 2008.
6. Cohen J. Infectious disease. Extensively drug-resistant TB gets foothold in South Africa. Science 2006; 313: 1554.
7. Gandhi N R, Moll A, Pawinski R. High prevalence and mortality from extensively-drug resistant (XDR-TB) TB in TB/HIV co-infected patients in rural South Africa. Toronto, Canada: XVI International AIDS Conference, 2006: pp 13-18 [Abstract THLB0210].
8. Gandhi N, Moll A, Sturm A W, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368: 1575-1580. (Pubitemid 44780738)
9. Kwoon Y S, Kim Y H, Suh G Y, et al. Treatment outcomes of HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clin Infect Dis 2008; 47: 496-502.
10. Pillay M, Sturm A W. Evolution of the extensively drug-resistant F15/LAM4/KZN strain of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa. Clin Infect Dis 2007; 45: 1409-1414.
11. Sun Z, Chao Y, Zhang X, et al. Characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates in China. J Clin Microbiol 2008; 46: 4075-4077.
12. Canetti G, Fox W, Khomenko A, et al. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ 1969; 41: 21-43.
13. Lee C N, Heifets L B. Determination of minimal inhibitory concentrations of antituberculosis drugs by radiometric and conventional methods. Am Rev Respir Dis 1987; 136: 349-352.
14. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved Standard NCCLS Document M7-A2. Villanova, PA, USA: NCCLS, 1993.
15. Hawkins J, Wallace R, Brown B. Antibacterial susceptibility tests: mycobacteria. In: Balows A, Hausler J, Herrmann K, Isenberg H, Shadomy H. Manual of clinical microbiology. 5th ed. Washington DC, USA: American Society for Microbiology, 1991: pp 1138-1152.
16. Vareldzis B P, Grosset J, de Kantor I, et al. Drug-resistant tuberculosis: laboratory issues. World Health Organization recommendations. Tubercle Lung Dis 1994; 75: 1-7.
17. World Health Organization. Guidelines for drug susceptibility testing for second-line anti-tuberculosis drugs for DOTS-Plus. WHO/CDS/TB/2001.288. Geneva, Switzerland: WHO, 2001.
18. Caws M, Drobniewski F A. Molecular techniques in the diagnosis of Mycobacterium tuberculosis and the detection of drug resistance. Ann NY Acad Sci 2001; 953: 138-145.
19. Shen X, Shen G, Wu J, et al. Association between embB codon 306 mutations and drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2007; 51: 2618-2620.
20. Safi H, Sayers B, Hazbón M H, Alland D. Transfer of embB codon 306 mutations into clinical Mycobacterium tuberculosis strains alters susceptibility to ethambutol, isoniazid, and rifampin. Antimicrob Agents Chemother 2008; 52: 2027-2034.
21. Caminero J A. Treatment of multidrug-resistant tuberculosis: evidence and controversies. Int J Tuberc Lung Dis 2006; 10: 829-837.
22. World Health Organization. Treatment of tuberculosis: guidelines for national programmes. 3rd ed. WHO/CDS/TB/2003. 313. Geneva, Switzerland: WHO, 2003.
23. Crofton J, Chaulet P, Maher D. Guidelines for the management of drug-resistant tuberculosis. Geneva, Switzerland: World Health Organization, 1997: pp 1-40.
24. Caminero J A. Likelihood of generating MDR-TB and XDRTB under adequate National Tuberculosis Control Programme implementation. Int J Tuberc Lung Dis 2008; 12: 869-877.
25. Zaczek A, Brzostek A, Augustynowicz-Kopec E, Zwolska Z, Dziadek J. Genetic evaluation of relationship between mutations in rpoB and resistance of Mycobacterium tuberculosis to rifampin. BMC Microbiol 2009; 9: 10.
26. Spies F S, de Silva P E, Ribeiro M O, Rossetti M L, Zaha A. Identification of mutations related to streptomycin resistance in clinical isolates of Mycobacterium tuberculosis and possible involvement of efflux mechanism. Antimicrob Agents Chemother 2008; 52: 2947-2949.
27. Sun Z, Zhang J, Zhang X, Wang S, Zhang Y, Li C. Comparison of gyrA gene mutations between laboratory-selected ofloxacin-resistant Mycobacterium tuberculosis strains and clinical isolates. Intl Antimicrob Agents 2008; 31: 115-121.
28. Heifets L B, Cangelosi G A. Drug susceptibility testing of Mycobacterium tuberculosis: a neglected problem at the turn of the century. Int J Tuberc Lung Dis 1999; 3: 564-581.